Skip to main content
Home

Language & Country Selector for Desktop

language-selector-globe Sandoz | en

Choose Location

  • Americas
  • Asia Pacific
  • Europe
  • International
  • Middle East & Africa
  • Argentina | es
  • Brazil | pt
  • Canada | en
  • Canada | fr
  • Mexico | es
  • United States | en
  • Australia | en
  • Japan | ja
  • Korea | ko
  • Mainland China | zh
  • Austria | de
  • Belgium | fr
  • Belgium | nl
  • Bulgaria | bg
  • Croatia | hr
  • Czech Republic | cs
  • Denmark | da
  • Finland | fi
  • France | fr
  • Germany | de
  • Hungary | hu
  • Italy | it
  • Netherlands | nl
  • Norway | no
  • Poland | pl
  • Portugal | pt
  • Romania | ro
  • Russia | ru
  • Slovakia | sk
  • Spain | es
  • Sweden | sv
  • Switzerland | de
  • Switzerland | fr
  • United Kingdom | en
  • Global | en
  • Sandoz | en
  • Saudi Arabia | ar
  • Turkey | tr

Language & Country Selector for Mobile

language-selector-globe Sandoz

Choose Location

Americas Asia Pacific Europe International Middle East & Africa
  • Argentina | es
  • Australia | en
  • Austria | de
  • Belgium | fr
  • Belgium | nl
  • Brazil | pt
  • Bulgaria | bg
  • Canada | en
  • Canada | fr
  • Croatia | hr
  • Czech Republic | cs
  • Denmark | da
  • Finland | fi
  • France | fr
  • Germany | de
  • Hungary | hu
  • Italy | it
  • Japan | ja
  • Korea | ko
  • Mainland China | zh
  • Mexico | es
  • Netherlands | nl
  • Norway | no
  • Global | en
  • Sandoz | en
  • Poland | pl
  • Portugal | pt
  • Romania | ro
  • Russia | ru
  • Saudi Arabia | ar
  • Slovakia | sk
  • Spain | es
  • Sweden | sv
  • Switzerland | de
  • Switzerland | fr
  • Turkey | tr
  • United Kingdom | en
  • United States | en
    • About Sandoz 
      • Our Purpose and Ambition 
      • What We Do 
      • Innovation, Quality and Supply 
      • Corporate Responsibility 
        • Ethics, Risk and Compliance 
        • Sandoz external funding 
        • Malaria Initiative 
        • Novartis Access 
        • World Child Cancer 
      • Our History 
      • Investor Information 
      A girl with a flower About Sandoz
    • Products & Services 
      • Disease Areas 
        • Anti-Infectives 
        • Respiratory 
        • Endocrinology 
        • Immunology 
        • Oncology 
      • Biopharmaceuticals 
        • Sandoz Biosimilars 
        • Sandoz Biosimilar Portfolio and Pipeline 
        • About Biologics 
        • Development of Biosimilars 
        • Information for Patients 
      • Prescription Medicines 
      • Over-The-Counter Medicines 
      • Partnerships and Collaborations 
        • Business to Business (B2B) 
        • Business to Business (B2B) 
        • Business to Business (B2B) 
      00181_300dpi_RGB Products & Services
    • People & Culture 
      • Sandoz Leadership 
        • Richard Saynor 
        • Francisco Ballester 
        • Martin Bischof 
        • Colin Bond 
        • Pierre Bourdage 
        • Valerie Chew 
        • Claire D'Abreu-Hayling 
        • Glenn A. Gerecke, PhD 
        • Rebecca Guntern 
        • Keren Haruvi 
        • Steffen Kurzawa 
        • Inge Maes 
        • Ingrid Sollerer 
      • Diversity & Inclusion 
      • Associate Stories 
    • Investors & Media 
      • Sandoz spin-off 
      • Media Releases 
      • Media Library 
      • Media Contacts 
      • Novartis Annual Reporting Suite 
    • Careers 
      • Working at Sandoz 
      • Diversity & Inclusion 
      • Associate Stories 
      • Job Search 
      Sandoz Careers Careers
    • News 
      • News Archive 
      • Media Releases 
      • Publications 
      • Stay Up-To-Date 
      A photo of people in a meeting hall News
    • Contacts 
    working at sandoz Home
  1. Home
  2. News
  3. All News
News Archive Navigation
  • All
  • Featured News
  • Media Release
icon
News Archive Navigation Language
  • English
  • French
  • German

January 2020

  • Media ReleaseJan 31, 2020
    Sandoz completes acquisition of Aspen’s Japanese operations, strengthening its position in world’s third largest market for generics and off-patent medicines
    Successful acquisition of Aspen’s Japanese operations and assets reinforces strategic focus on Japan, world’s third largest market for generics and off-patent medicines Acquired portfolio…
  • Media ReleaseJan 30, 2020
    Sandoz officially recognized as Global Top Employer 2020
    Sandoz officially recognized by Top Employers Institute for its exceptional employee offerings globally People-first policies such as global equal parental leave for 14 weeks and joining the Equal…
  • Media ReleaseJan 29, 2020
    Novartis delivered strong sales growth, margin expansion and breakthrough innovation launching five NMEs in 2019
    Full year net sales for continuing operations1 up 9% (cc2, +6% USD): Pharmaceuticals BU growing 12% (cc) driven by Cosentyx USD 3.6 billion (+28% cc), Entresto USD 1.7 billion (+71% cc) and…

November 2019

  • Media ReleaseNov 12, 2019
    Sandoz presents real-world data showing effectiveness of Erelzi® (etanercept-szzs) in rheumatic disease treatment
    Interim results from COMPACT, a multi-country, real-world study of Erelzi for approved rheumatic diseases presented at 2019 ACR/ARP Annual Meeting US analysis of long-term financial impact when…
  • Media ReleaseNov 11, 2019
    Sandoz announces agreement to acquire Aspen’s Japanese operations and associated assets, strengthening position in world’s third largest generics market
    Planned acquisition reinforces Sandoz strategic focus on Japan Aspen portfolio in Japan consists primarily of off-patent branded medicines with focus on anesthetics and specialty brands Medicines…
  • Media ReleaseNov 05, 2019
    Sandoz receives US FDA approval for long-acting oncology supportive care biosimilar ZiextenzoTM (pegfilgrastim-bmez)
    Ziextenzo™ is indicated to decrease the incidence of febrile neutropenia, one of the most serious side effects of chemotherapy With approval of Ziextenzo™ , Sandoz is first and only company to offer…

October 2019

  • Media ReleaseOct 22, 2019
    Novartis delivered another strong quarter with double digit sales growth and core1 margin expansion; 2019 sales and profit guidance raised; Beovu launched in US
    Continuing operations2 net sales up 13% (cc1, +10% USD) driven by: Cosentyx sales of USD 937 million (+27% cc), with strong demand across indications and regions Entresto USD 430 million (+61% cc…

September 2019

  • Media ReleaseSep 03, 2019
    Sandoz announces global deal to commercialize proposed biosimilar natalizumab, a key multiple sclerosis medicine
    Worldwide agreement with Polpharma Biologics gives Sandoz commercialization rights to proposed biosimilar natalizumab for relapsing-remitting multiple sclerosis (RRMS) RRMS affects ~85% of MS…

August 2019

  • Media ReleaseAug 09, 2019
    Sandoz will appeal District Court of New Jersey ruling in biosimilar Erelzi® (etanercept-szzs) US patent case
    Sandoz to appeal court ruling to United States Court of Appeals for the Federal Circuit Ruling prevents launch of important, affordable treatment option for US patients affected by chronic…

July 2019

  • Media ReleaseJul 22, 2019
    Sandoz announces first patient enrolled in clinical study for proposed biosimilar denosumab in osteoporosis
    Integrated Phase I/lll study for proposed biosimilar denosumab to confirm matching efficacy, safety and immunogenicity with reference medicine1 Osteoporosis accounts for 8.9m bone fractures…
  • Media ReleaseJul 18, 2019
    Novartis delivers strong sales, double digit core operating income growth and launches Zolgensma and Piqray in second quarter; sales and profit guidance increased
    Continuing operations1 net sales up 8% (cc2, +4% USD) driven by: Cosentyx at USD 858 million, +25% (cc) mainly driven by continued strong US growth (+31%) Entresto grew to USD 421 million, +81% (…
  • Media ReleaseJul 09, 2019
    Sandoz extends SYMJEPI™ (epinephrine) Injection launch to US pharmacies to help improve patient access to life-saving medicine
    Adult and pediatric doses immediately available as single-dose, pre-filled syringe and device combination for emergency treatment of Type 1 allergic reactions, including anaphylaxis1 SYMJEPI will…

Pagination

  • ‹ Previous page
  • …
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • …
  • › Next page

Sandoz Global

Key resources
  • Patients & Caregivers
  • Job seekers
  • Investors
  • Media
Recent updates
  • Sandoz spin-off
Explore
  • Contacts
  • Locations
  • Biosimilar Portfolio and Pipeline
Sandoz Companies
  • 1A Pharma
  • Hexal
  • Lek
Footer Bottom
© 2023 Sandoz International GmbH
  • Terms of Use
  • Privacy Policy
  • About Cookies
  • Legal Notice
  • Social Media Community Guidelines
  • Cookie Settings
  • Site Map
  • Web Accessibility
Novartis Site Directory
This site is intended for a global audience